Answers are grounded in this paper and cite their sources.
Aberrant PD-L1 expression and persistent internalization, driving immune evasion and resistance lead to limited immune checkpoint therapeutic efficacy on hepatocellular carcinoma (HCC). Selenium (Se) deficiency downregulates selenoprotein levels and drives immune cell exhaustion. However, whether Se enhances the therapeutic efficiency of PD-L1/PD-1 checkpoint blockade in HCC remains unclear. Here, we identify a selenoprotein-dependent mechanism that promotes targeted PD-L1 degradation and enhances antitumor immunity. Se reduces PD-L1 abundance in tumors to promote antitumor immunity and synergizes with anti-PD-1 antibodies to suppress tumor growth in a tumor-bearing mice model. Mechanistically, Se inhibits the AKT/SLC7A11/HIF-1α signaling cascade, thereby blocking the inflammatory signaling transduction and suppressing de novo PD-L1 synthesis. Se also induces GPX2 and TrxR1 expression, which directly targets the IgC domain PD-L1 and initiates lysosome-dependent degradation. Genetic knockdown of GPX2 and TrxR1 abrogates Se-mediated PD-L1 downregulation and diminishes its immunostimulatory effects. Consistently, analyses of human normal liver, primary HCC, and metastatic tissues reveal a significant inverse correlation between GPX2/TrxR1 expression and PD-L1 levels, which further suggests the critical roles of GPX2 and TrxR1 in controlling HCC progression. Collectively, these findings uncover a selenoprotein-driven PD-L1 degradation pathway, which may shed light on the application of establishing a new paradigm of selenoprotein-mediated lysosomal degradation for HCC immunotherapy.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: